One factor that may underlie variation in clinical outcomes of COVID-19 is the extent of gene expression in the airway of the SARS-CoV-2 entry receptor, ACE2, and TMPRSS2, the host protease that cleaves the viral spike protein and thus allows for efficient virus-receptor binding8. This evidence concerns the gene TMPRSS2 and COVID-19.